Philips’ CoreVision iFR co-registration solution coupled with the Core IVUS and physiology technology, can be utilized in the stenting process when lesions are more complex. CoreVision can be used in any interventional lab to map pressure gradients onto the angiogram for precise lesion location, severity and length measurements.

Therapeutic devices
The recent acquisition of Spectranetics expands Philips’ range of therapy devices for coronary and peripheral artery disease. At this year’s congress, Philips will feature the Stellarex drug-coated balloon. Stellarex delivers top-tier clinical results for common to complex patients, targeting an underserved need in the fast growing peripheral vascular market. As the only commercially available drug-coated balloon with two reported randomized controlled trials, Stellarex has demonstrated durability with consistently high patency rates in a wide range of patients.


“TCT provides the opportunity for us to share our expanded portfolio that aims to help those affected by cardiovascular disease to get back to living their lives,” said Bert van Meurs, Business Leader Image Guided Therapy for Philips. “At the congress this year, we’ll demonstrate how we’re furthering our goal to help clinicians decide, guide, treat and confirm the right therapies for their patients and provide safe and personalized treatments to enable faster recoveries while reducing costs.”

In its TCT booth this year, Philips will also host a series of short, daily presentations and live case demonstrations on optimizing patient care for cardiovascular disease. Additionally, Philips and Spectranetics will hold a lunch symposium each day of TCT on various topics including, “State-of-the-art” PCI approach (learnings from SYNTAX II), imaging technologies for new valve therapies, and optimizing outcomes in coronary artery disease.

For the full calendar of daily presentations, as well as general information about Philips’ presence at the show, visit www.philips.com/tct. Visit the Philips and Spectranetics booths (#1029 and #4133) to experience innovative cardiac solutions that deliver across the full health continuum. Follow the #TCT17 conversation on @PhilipsLiveFrom throughout the event.

[1] Heart Disease and Stroke Statistics 2017. At –a– Glance. American Heart Association, January 2017


About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 73,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Back to HCB News

Cardiology Homepage